Methylprednisolone
Depo-medrol, Medrol, Neo-medrol, Solu-medrol (methylprednisolone) is a small molecule pharmaceutical. Methylprednisolone was first approved as Medrol on 1982-01-01. It is used to treat adrenal insufficiency, ankylosing spondylitis, asthma, atopic dermatitis, and berylliosis amongst others in the USA. The pharmaceutical is active against glucocorticoid receptor. In addition, it is known to target short transient receptor potential channel 5.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| neoplasms | D009369 |
| musculoskeletal diseases | D009140 |
| digestive system diseases | D004066 |
| respiratory tract diseases | D012140 |
| nervous system diseases | D009422 |
| eye diseases | D005128 |
| urogenital diseases | D000091642 |
| hemic and lymphatic diseases | D006425 |
| hereditary congenital and neonatal diseases and abnormalities | D009358 |
Show 7 more
Trade Name
FDA
EMA
Depo-medrol, Medrol, Solu-medrol (generic drugs available since 1997-10-16, discontinued: A-methapred, M-predrol, Medrol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methylprednisolone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MEDROL | Mylan | N-011153 RX | 1982-01-01 | 5 products, RLD, RS |
Show 1 discontinued
Methylprednisolone acetate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DEPO-MEDROL | Mylan | N-011757 RX | 1982-01-01 | 3 products, RLD |
Show 2 discontinued
Methylprednisolone sodium succinate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SOLU-MEDROL | Pharmacia & Upjohn | N-011856 RX | 1982-01-01 | 5 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| depo-medrol | New Drug Application | 2023-06-13 |
| methylprednisolone sodium succinate | ANDA | 2023-06-20 |
| solu-medrol | New Drug Application | 2023-05-30 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| adrenal insufficiency | — | D000309 | — |
| ankylosing spondylitis | EFO_0003898 | D013167 | M45 |
| asthma | EFO_0000270 | D001249 | J45 |
| atopic dermatitis | EFO_0000274 | D003876 | L20 |
| berylliosis | EFO_0007168 | D001607 | J63.2 |
| brain neoplasms | EFO_0003833 | D001932 | C71 |
| dermatitis herpetiformis | — | D003874 | L13.0 |
| erythema multiforme | — | D004892 | L51 |
| graft vs host disease | — | D006086 | D89.81 |
| hematologic diseases | EFO_0005803 | D006402 | D75.9 |
Show 18 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D07: Corticosteroids, dermatological preparations
— D07A: Corticosteroid dermatological preparations, plain
— D07AA: Corticosteroids, weak (group i)
— D07AA01: Methylprednisolone
— D07AC: Corticosteroids, potent (group iii)
— D07AC14: Methylprednisolone aceponate
— D07C: Corticosteroids, combinations with antibiotics
— D07CA: Corticosteroids, weak, combinations with antibiotics
— D07CA02: Methylprednisolone and antibiotics
— D10: Anti-acne preparations
— D10A: Anti-acne preparations for topical use
— D10AA: Corticosteroids, combinations for treatment of acne
— D10AA02: Methylprednisolone
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H02: Corticosteroids for systemic use
— H02A: Corticosteroids for systemic use, plain
— H02AB: Glucocorticoids, systemic
— H02AB04: Methylprednisolone
— H02B: Corticosteroids for systemic use, combinations
— H02BX: Corticosteroids for systemic use, combinations
— H02BX01: Methylprednisolone, combinations
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01C: Antiinflammatory agents and antiinfectives in combination
— S01CA: Corticosteroids and antiinfectives in combination, opthalmologic
— S01CA08: Methylprednisolone and antiinfectives
HCPCS
Code | Description |
|---|---|
| J1020 | Injection, methylprednisolone acetate, 20 mg |
| J1030 | Injection, methylprednisolone acetate, 40 mg |
| J1040 | Injection, methylprednisolone acetate, 80 mg |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg |
| J7509 | Methylprednisolone oral, per 4 mg |
Clinical
Clinical Trials
1209 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | C85.9 | 10 | 33 | 20 | 1 | 8 | 69 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 5 | 15 | 11 | 9 | 2 | 39 | |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 3 | 13 | 9 | 11 | 1 | 36 |
| Prostatic neoplasms | D011471 | C61 | 4 | 14 | 11 | 2 | 4 | 31 | |
| Asthma | D001249 | EFO_0000270 | J45 | 2 | 4 | 7 | 9 | 6 | 28 |
| Cataract | D002386 | EFO_0001059 | H26.9 | — | 1 | 7 | 16 | 2 | 26 |
| Covid-19 | D000086382 | U07.1 | — | 7 | 13 | 3 | 5 | 25 | |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 4 | 6 | 6 | 5 | 3 | 23 |
| Inflammation | D007249 | 2 | 2 | 6 | 8 | 3 | 20 | ||
| Kidney transplantation | D016030 | 1 | 5 | 6 | 6 | 1 | 18 |
Show 160 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | C95 | 9 | 41 | 13 | — | 8 | 64 | |
| Myelodysplastic syndromes | D009190 | D46 | 7 | 30 | 2 | — | 4 | 39 | |
| Graft vs host disease | D006086 | D89.81 | 5 | 19 | 9 | — | 5 | 35 | |
| Plasma cell neoplasms | D054219 | 3 | 9 | 2 | — | 4 | 18 | ||
| Non-hodgkin lymphoma | D008228 | C85.9 | 2 | 13 | 1 | — | — | 14 | |
| Neoplasms | D009369 | C80 | 3 | 5 | 3 | — | 1 | 12 | |
| Multiple myeloma | D009101 | C90.0 | 3 | 6 | 2 | — | — | 11 | |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 6 | 3 | — | 2 | 10 |
| Iga glomerulonephritis | D005922 | EFO_0004194 | — | 3 | 6 | — | 2 | 9 | |
| Alcoholic hepatitis | D006519 | EFO_1001345 | K70.1 | 1 | 4 | 3 | — | 2 | 9 |
Show 108 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloproliferative disorders | D009196 | D47.1 | 3 | 7 | — | — | 2 | 12 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 2 | 11 | — | — | — | 11 | |
| Myelodysplastic-myeloproliferative diseases | D054437 | 1 | 8 | — | — | 2 | 11 | ||
| Fanconi anemia | D005199 | Orphanet_84 | D61.09 | 3 | 6 | — | — | 1 | 8 |
| Neuroblastoma | D009447 | EFO_0000621 | 1 | 5 | — | — | — | 6 | |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | — | 6 | — | — | — | 6 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | 4 | — | — | — | 4 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 4 | — | — | — | 4 |
| Myeloid leukemia chronic-phase | D015466 | — | 3 | — | — | — | 3 | ||
| Myelomonocytic leukemia juvenile | D054429 | C93.3 | 1 | 3 | — | — | — | 3 |
Show 106 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | 3 | — | — | — | — | 3 | ||
| Inflammatory bowel diseases | D015212 | EFO_0003767 | 1 | — | — | — | 1 | 2 | |
| Myositis | D009220 | EFO_0000783 | G72.49 | 1 | — | — | — | 1 | 2 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | — | — | — | — | 1 |
| T-cell lymphoma | D016399 | 1 | — | — | — | — | 1 | ||
| T-cell leukemia | D015458 | 1 | — | — | — | — | 1 | ||
| Syndrome | D013577 | 1 | — | — | — | — | 1 | ||
| Lymphoid leukemia | D007945 | C91 | 1 | — | — | — | — | 1 | |
| Innate immunity | D007113 | 1 | — | — | — | — | 1 | ||
| Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 |
Show 13 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intervertebral disc displacement | D007405 | EFO_1001800 | — | — | — | — | 2 | 2 | |
| Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 2 | 2 | |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 2 | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 2 | 2 |
| Blood pressure | D001794 | EFO_0004325 | — | — | — | — | 2 | 2 | |
| Pathologic dilatation | D004108 | — | — | — | — | 2 | 2 | ||
| Regeneration | D012038 | — | — | — | — | 2 | 2 | ||
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | — | — | 1 | 1 |
| Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | — | — | — | — | 1 | 1 |
| Hypertrophic cicatrix | D017439 | L91.0 | — | — | — | — | 1 | 1 |
Show 54 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | METHYLPREDNISOLONE |
| INN | methylprednisolone |
| Description | 6alpha-methylprednisolone is the 6alpha-stereoisomer of 6-methylprednisolone. It has a role as an anti-inflammatory drug, a neuroprotective agent, an antiemetic, an adrenergic agent, a xenobiotic and an environmental contaminant. It is a 6-methylprednisolone, a primary alpha-hydroxy ketone and a tertiary alpha-hydroxy ketone. |
| Classification | Small molecule |
| Drug class | steroids (not prednisolone derivatives); prednisone and prednisolone derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |
Identifiers
| PDB | — |
| CAS-ID | 83-43-2 |
| RxCUI | 6902 |
| ChEMBL ID | CHEMBL650 |
| ChEBI ID | 6888 |
| PubChem CID | 6741 |
| DrugBank | DB00959 |
| UNII ID | X4W7ZR7023 (ChemIDplus, GSRS) |
Target
Agency Approved
NR3C1
NR3C1
Organism
Homo sapiens
Gene name
NR3C1
Gene synonyms
GRL
NCBI Gene ID
Protein name
glucocorticoid receptor
Protein synonyms
Nuclear receptor subfamily 3 group C member 1, nuclear receptor subfamily 3 group C member 1 variant hGR-B(54), nuclear receptor subfamily 3 group C member 1 variant hGR-B(77), nuclear receptor subfamily 3 group C member 1 variant hGR-B(93), nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
Uniprot ID
Mouse ortholog
Nr3c1 (14815)
glucocorticoid receptor (Q61629)
Alternate
TRPC5
TRPC5
Organism
Homo sapiens
Gene name
TRPC5
Gene synonyms
TRP5
NCBI Gene ID
Protein name
short transient receptor potential channel 5
Protein synonyms
hTRP-5, hTRP5, protein phosphatase 1, regulatory subunit 159, transient receptor potential channel 5, Transient receptor protein 5, TRP-5
Uniprot ID
Mouse ortholog
Trpc5 (22067)
short transient receptor potential channel 5 (Q9R0D4)
Variants
Clinical Variant
No data
Financial
Medrol - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 63,073 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
77 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more